Navigation Links
Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns
Date:4/18/2011

WATERTOWN, Mass., April 18, 2011 /PRNewswire/ -- Measuring the body temperatures of newborns with temporal artery thermometry (forehead scanning) provides readings comparable to results obtained by axillary (under arm) thermometry, the clinically recommended method for this patient population, but causes less discomfort, according to a new study reported in Advances in Neonatal Care.  

The study(1), the first published clinical analysis evaluating the accuracy of temporal artery thermometry in neonates, compared the accuracy of temporal artery and axillary temperature readings as well as the discomfort level of newborns while obtaining the temperature readings. The sample included stable, mostly normothermic newborns with a gestational age between 32 and 40 weeks at birth hospitalized in a neonatal intensive care unit (NICU).  Rectal thermometry was used as the reference.

Researchers noted that axillary temperatures measured with an electronic thermometer probe are difficult to obtain without disturbing newborns, such disturbances causing increased respiratory and heart rates and lower oxygen saturation.  During the study, measurements taken using temporal artery thermometry resulted in a statistically significant improvement in comfort scores.  

An excerpt from the published study confirms this: "Neonates experienced less discomfort with the temporal artery thermometer than with the axillary thermometer method."  In addition, the authors stated: "The statistical equivalency of the temporal artery and axillary temperatures, coupled with less discomfort to the neonate during temporal artery device use, makes the temporal artery thermometer an attractive alternative for temperature monitoring in neonates."

"This independent research validates our findings about the usefulness of temporal artery thermometry," said Francesco Pompei, Ph.D., CEO of Exergen Corp. "Exergen's patented TemporalScanner™ Thermometer was developed in response to healthcare providers' and caregivers' at home need for a gentle, noninvasive, and accurate method of thermometry for all ages, from newborns to geriatrics."

The clinical research, which used an infra-red electronic temperature device made by Exergen Corp., was conducted at a level IIIa NICU in a not-for-profit hospital in the Western United States. It showed body temperature readings taken at the temporal artery and the clinically recommended under the arm method were similarly accurate when compared to rectal thermometry. The amount of deviation from the reference readings was within the standard set for noninvasive temperature measurement.

The study was not affiliated with Exergen and neither the authors nor the institution received compensation from the company to conduct the research.

Exergen markets two models of the TemporalScanner thermometer: a professional version for doctors' offices and hospitals, and a consumer model sold in major retailers including Wal-Mart, Target, Walgreen's, Costco, Sam's Club, Babies "R" Us, Toys "R" Us, and BJ's. More than 800 million temperatures are taken each year with the TemporalScanner. Used in thousands of hospitals, clinics, and pediatricians' offices in the country as well as in millions of homes, it is also the only thermometer manufactured in the United States.  

Exergen Corporation is recognized worldwide as an innovator and leading manufacturer of patented infrared thermometers, scanners, sensors and controls. The company holds more than 60 U.S. patents for non-invasive temperature measurement devices. Its products are used in a wide variety of industrial and medical applications for both professionals and consumers. For additional information, visit www.exergen.com.

(1) Gail Lee, RN, et al; Accuracy of Temporal Artery Thermometry in Neonatal Intensive Care Infants, in Advances in Neonatal Care,  Vol. 11, No. 1, pp 62-70.


'/>"/>
SOURCE Exergen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
2. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
3. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
4. Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting
5. Analytical Bio-Chemistry (ABC) Laboratories Implements eStudy™ Hosted Platform to Support its Ecotoxicology and Other Service Offerings
6. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
7. Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
8. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
9. New Published Study Finds Masimo SET® Delivers More Reliable Measurements Significantly Faster Than Other Pulse Oximetry Technologies
10. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
11. Study Highlights Successes of Ascension Health Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
Breaking Medicine Technology:
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
(Date:2/17/2017)... ... 17, 2017 , ... Program will serve more than 5,000 ... U.S. Soccer Foundation announced today that they have awarded nine grants to expand ... Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving to ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... ... Top neuroendocrine cancer doctors, nurses and specialists from around the world will ... in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive director of ... hosting over 60 faculty members and addressing unmet needs of the NET community. ...
Breaking Medicine News(10 mins):